References


References


References


Davies SW, Marchant B, Lyons JP, et al. Irregular coronary lesion morphology after thrombolysis predicts early
References


Erickson LA, Ginsberg MH, Loskuthoff DJ. Detection and partial characterization of an inhibitor of


**Falk E.** Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol 1991;68:28B-35B.


**Fears R, Ferres H, Glasgow E, et al.** Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. Br Heart J 1992;68:167-70.


**FitzGerald DJ, FitzGerald GA.** Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci USA 1989;86:7585-9.


References


Gil V, Antunes A, Ventosa A, Morais J, Seabra-Gomes R, on behalf of the Portuguese Cooperative Group on Ventricular Function of the LATE Study. Late thrombolysis with alteplase improves left ventricular ejection fraction at 1 month after myocardial infarction - a double blind, placebo controlled study. J Am Coll Cardiol 1993;21:300A.


Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989;86;3847-51.


References


Kruithof EKO, Tran-Thanh C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen


LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.

Lee HS, Cross S, Davidson R, Reid T, Jennings K. Raised levels of antistreptokinase antibody and neutralization titers from 4 days to 54 months after administration of streptokinase or anistreplase. Eur Heart J 1993;14:84-9.


References


References


Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633-44.


Ridker PM, Hebert PR, Fuster V, Hennekens CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for myocardial infarction. Lancet 1993;341:1574-7.

References


Shah PK. The role of thrombolytic therapy in patients with acute myocardial infarction presenting later than six hours after the onset of symptoms. Am J Cardiol 1991;68:72C-77C.


Silver MD, Baroldi G, Mariani F. The relationship between acute occlusive coronary thrombi and myocardial


Toffler GH, Brezinski D, Schager AI, et al. Concurrent morning increase in platelet aggregability and the risk of
 References


Verstraete M. Intravenous administration of a thrombolytic treatment is the only realistic therapeutic approach in evolving myocardial infarction. Eur Heart J 1985;6:586-93.


Weaver DW, Cerqueira M, Hallstrom AP, et al. for the myocardial infarction triage and intervention project group. Prehospital-initiated vs hospital-initiated thrombolytic therapy -The myocardial infarction triage and intervention (MITI) trial. JAMA 1993;270:1211-6 (a).


References


